Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?

Company Overview - Biogen Inc. (BIIB) shares increased by 5.7% to close at $120.49, following a broader market rally after President Trump's announcement of a 90-day pause on tariffs against non-retaliating countries [1] - The stock had previously experienced a 20.6% loss over the past four weeks [1] Earnings Expectations - Biogen is expected to report quarterly earnings of $3.59 per share, reflecting a year-over-year decline of 2.2% [2] - Revenue projections stand at $2.24 billion, also down 2.2% from the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for Biogen has remained unchanged over the last 30 days, indicating a lack of upward momentum in earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Comparison - Biogen operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Qiagen (QGEN), saw a 6.8% increase in its stock price, closing at $41.43 [3] - Qiagen's consensus EPS estimate is $0.49, representing a year-over-year increase of 4.3%, with its Zacks Rank also at 3 (Hold) [4]